Document Detail


Deferasirox administration for the treatment of non-transfusional iron overload in patients with thalassaemia intermedia.
MedLine Citation:
PMID:  20950401     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Abnormal iron regulation in patients with thalassaemia intermedia may lead to iron overload even in the absence of transfusions. There are limited data on iron chelator use in patients with thalassaemia intermedia and no guidelines exist for the management of iron overload. We present data from 11 patients with thalassaemia intermedia treated with deferasirox (Exjade(®) , 10-20 mg/kg/d) for 24 months. Liver iron concentration and serum ferritin levels significantly decreased over the first 12 months (P = 0·005) and continued to decrease over the remainder of the study (P = 0·005). This small-scale study indicated that deferasirox may be suitable for controlling iron levels in patients with thalassaemia intermedia.
Authors:
Vassilis Ladis; Helen Berdousi; Efstathios Gotsis; Antonis Kattamis
Publication Detail:
Type:  Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't     Date:  2010-10-18
Journal Detail:
Title:  British journal of haematology     Volume:  151     ISSN:  1365-2141     ISO Abbreviation:  Br. J. Haematol.     Publication Date:  2010 Dec 
Date Detail:
Created Date:  2010-11-12     Completed Date:  2011-01-03     Revised Date:  2013-06-03    
Medline Journal Info:
Nlm Unique ID:  0372544     Medline TA:  Br J Haematol     Country:  England    
Other Details:
Languages:  eng     Pagination:  504-8     Citation Subset:  IM    
Copyright Information:
© 2010 Blackwell Publishing Ltd.
Affiliation:
First Department of Paediatrics, Athens University, Thalassaemia Unit, Aghia Sofia Children's Hospital Encephalos-Euromedica Laboratories, Rizariou 3, Halandri, Athens Greece. thalas@paidon-agiasofia.gr
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Benzoates / adverse effects,  therapeutic use*
Female
Ferritins / blood
Humans
Iron / metabolism
Iron Chelating Agents / adverse effects,  therapeutic use*
Iron Overload / diagnosis,  drug therapy*,  etiology,  metabolism
Liver / metabolism
Magnetic Resonance Imaging
Male
Treatment Outcome
Triazoles / adverse effects,  therapeutic use*
Young Adult
beta-Thalassemia / complications*,  metabolism
Chemical
Reg. No./Substance:
0/Benzoates; 0/Iron Chelating Agents; 0/Triazoles; 7439-89-6/Iron; 9007-73-2/Ferritins; V8G4MOF2V9/deferasirox
Comments/Corrections
Erratum In:
Br J Haematol. 2011 Jan;152(1):124

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Significance levels in genome-wide interaction analysis (GWIA).
Next Document:  Increased phosphatidylserine exposure on the erythrocyte membrane in patients with polycythaemia ver...